Wednesday, June 26, 2019 4:23:32 PM
On the daily chart of NYSE:MRK it seems that a nice breakout rally is setting up, with $84 as a good point to evaluate your position. The chart accompanying this post is merely a look at the nature of declines that a stock can suffer, to get back to the 2000 price level may take a possible 21 years, that is a long to hold and pray. It teaches us the lesson that stocks can keep going down, so accept you lose quickly and don't wait 20 years for it to claw its way back. Every company that we invest in is just one mistake or headline away from the fate of falling like a stone and the only ones left holding on are those who just couldn't accept the loss in the hope it will be different next week.
"even the mighty can fall"
AVERAGE ANALYSTS PRICE TARGET $88
AVERAGE ANALYSTS RECOMMENDATION BUY
P/E RATIO 26
COMPANY PROFILE
Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines , vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical , Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.
Official InvestorsHub (IHUB) Profile for TopMarketGainers.com. Since 2009,
we are the #1 Source For #FREE Winning #NASDAQ & #NYSE-Listed Alerts!
IHUB Board: https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Recent MRK News
- Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-conta • PR Newswire (Canada) • 04/19/2024 11:04:00 AM
- Santé Canada approuve KEYTRUDA® comme traitement de première intention, en association avec une chimiothérapie à base de fluoropyrimidine et de platine, des adultes atteints d'un adénocarcinome gastrique ou de la jonction gastro-œsophagienne (JGO) H • PR Newswire (Canada) • 04/19/2024 11:04:00 AM
- Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News • IH Market News • 04/10/2024 11:13:48 AM
- Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer • Business Wire • 04/04/2024 10:45:00 AM
- REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer • Business Wire • 04/03/2024 12:00:00 PM
- Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25 • Business Wire • 04/01/2024 10:45:00 AM
- European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults • Business Wire • 03/28/2024 10:45:00 AM
- GameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More News • IH Market News • 03/27/2024 10:54:47 AM
- FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1) • Business Wire • 03/26/2024 10:21:00 PM
- Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer • Business Wire • 03/21/2024 10:45:00 AM
- Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults • Business Wire • 03/19/2024 01:00:00 PM
- FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform • PR Newswire (US) • 03/15/2024 08:23:00 PM
- Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer • Business Wire • 03/15/2024 10:45:00 AM
- Merck Announces Plans to Conduct Clinical Trials of a Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9 • Business Wire • 03/13/2024 07:00:00 AM
- Merck Completes Acquisition of Harpoon Therapeutics, Inc. • Business Wire • 03/11/2024 12:15:00 PM
- Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24 • Business Wire • 03/06/2024 03:25:00 PM
- Futures Pointing To Continued Weakness On Wall Street • IH Market News • 03/05/2024 02:03:27 PM
- Merck to Participate in the Barclays 26th Annual Global Healthcare Conference • Business Wire • 03/05/2024 11:45:00 AM
- Merck to Participate in the Leerink Partners Global Biopharma Conference 2024 • Business Wire • 03/04/2024 11:45:00 AM
- Merck to Participate in the TD Cowen 44th Annual Health Care Conference • Business Wire • 02/27/2024 11:45:00 AM
- Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence • Business Wire • 02/23/2024 11:20:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:14:41 PM
- FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma • Business Wire • 02/20/2024 11:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:03:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:01:31 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM